The international summit on genome editing kicked off on Tuesday at the headquarters of the National Academy of Sciences, Washington, D.C. Several scientists and researchers gathered for the three-day conference that will discuss the scientific, ethical and governance issues associated with human gene-editing technologies.
The summit particularly focuses on whether gene editing of human embryos for therapeutic reasons should be considered or ruled out altogether, The Guardian noted.
“The overriding question is when, if ever, we will want to use gene editing to change human inheritance," summit chair David Baltimore of Caltech said in his introductory remarks. “We are close to altering human heredity and we need to decide how we as a society are going to use this capability.”
According to The Australian, the process fixing defecting genes is very complicated, so much so that it has slowed down the development of genetic therapies. With gene editing technology, scientists use molecular tools to repair or replace a defective gene or delete it.
A new tool called CRISPR-Cas9 has been adopted by laboratories worldwide as it is faster, economical, and simple enough to use with minimal level of training. Scientists hope to use the tool for diseases like sickle cell, fixing the defective gene in someone's own blood-producing cells instead of implanting donated ones.
Jennifer Doudna of the University of California at Berkeley is one of the pioneers of the CRISPR technology. Doudna told reporters that it will still take several years before the tool can be used for treatment of human diseases, The Washington Post reported.
"We don't understand enough yet about the human genome, and how genes interact, and which genes give rise to certain traits to edit for human enhancement today," she said.
Marcy Darnovsky of the Center for Genetics and Society advocacy group, however, opposes heritable gene editing and calls it potentially a "society-altering technology."


Microsoft Eyes Legal Action as Amazon-OpenAI Deal Threatens Azure Exclusivity
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes
Nvidia Develops Groq AI Chips for Chinese Market Amid Export Shift
Malaysia Semiconductor Industry Eyes Helium Supply Risks Amid Middle East Conflict
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI
OpenAI's Desktop Superapp: Unifying ChatGPT, Codex, and Browser Tools for Enterprise AI
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security
Alibaba Bets on AI Agents to Unify Its Vast Digital Ecosystem
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 



